For example, elevated plasma miR-370-3p levels correlate with poor prognosis in pancreatic ductal adenocarcinoma,[19] and in breast cancer, it can promote progression via the FBLN5/NF-κB axis.[20] It is important to note that miR-370-3p can also exert tumor-suppressive effects, as seen in nonfunctional pituitary adenomas where it targets HMGA2,[21] and in glioblastoma where it suppresses stem-like cell malignancy.[22] This functional duality underscores that the ultimate effect of a miRNA is dictated by its specific target repertoire within a given cellular microenvironment. The gene discussed is FBLN5; the disease is breast carcinoma.